Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib and Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT04963153Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of erdafitinib and enfortumab vedotin in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events up to 2 years, Recommended phase II dose up to 28 days and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
erdafitinibenfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04963153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963153.